Loading...

Major Indexes

Operating Data

Abbott Laboratories

Abbott Laboratories (ABT)

$79.34
4.78 (+6.41%)

Year
A/P
2013
Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue 21,848.0020,246.5420,404.4620,853.3627,390.8930,579.1931,906.3334,190.8236,638.8839,262.2342,073.40
Revenue (%)
EBITDA 4,347.754,146.494,337.994,702.435,658.966,959.827,545.857,388.647,917.668,484.579,092.06
EBITDA (%)
EBIT 2,628.312,597.632,866.833,184.311,725.633,651.164,530.704,232.824,535.894,860.665,208.69
EBIT (%)
Depreciation 1,719.441,548.861,471.161,518.123,933.333,308.673,015.153,155.813,381.773,623.903,883.38
Depreciation (%)




EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT)
EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income)
EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization
EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company
(1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments),
(2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill)
(3*) collections of assets (by ignoring depreciation of assets)
(4*) different takeover histories (by ignoring amortization often stemming from goodwill)